Last reviewed · How we verify
Clindamycin Gel (clindamycin )
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Acne vulgaris (topical), Bacterial skin infections (topical).
At a glance
| Generic name | Clindamycin Gel (clindamycin ) |
|---|---|
| Sponsor | Stiefel, a GSK Company |
| Drug class | Lincosamide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin binds to the bacterial 50S ribosomal subunit and inhibits peptide bond formation, preventing bacterial protein synthesis. This bacteriostatic action is effective against a broad range of gram-positive and anaerobic bacteria. When formulated as a topical gel, it is particularly useful for treating acne by reducing Cutibacterium acnes (formerly Propionibacterium acnes) colonization on the skin.
Approved indications
- Acne vulgaris (topical)
- Bacterial skin infections (topical)
Common side effects
- Dryness or peeling at application site
- Erythema or irritation at application site
- Oiliness or greasiness
- Folliculitis
Key clinical trials
- Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel) (NA)
- Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris (PHASE4)
- Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Therapeutic Management of Periodontitis and Clinical Manifestations of Rheumatoid Arthritis (NA)
- Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel (PHASE2)
- Effect of Intracanal Medicaments on Post-Operative Pain in Symptomatic Apical Periodontitis: An RCT (NA)
- Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clindamycin Gel (clindamycin ) CI brief — competitive landscape report
- Clindamycin Gel (clindamycin ) updates RSS · CI watch RSS
- Stiefel, a GSK Company portfolio CI